Komori
Governance4503Astellas Pharma Inc.Pharmaceuticals

Notice Regarding the Continuation of the Performance-Linked Stock Compensation Plan

The Company has decided to continue using the existing BIP Trust for performance-linked stock compensation for directors and implement a three-year incentive plan for fiscal 2026. The trust funding is expected to be ¥1,116 million.

Worth reading
—
Scored from 0 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1116
million yen
Wording
Conditional
How definitive the wording is.

Governance structure

Committee1
Compensation committee
Changes this time

The Company will continue using the existing BIP Trust established in fiscal 2023 and implement an incentive plan for fiscal 2026.

Governance structure
ItemDetails
CommitteeCompensation committee (percentage of outside members: not disclosed)
Changes this timeThe Company will continue using the existing BIP Trust established in fiscal 2023 and implement an incentive plan for fiscal 2026.
Items this document does not state (6)
Corporate Governance StructureNumber of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To promote management focused on enhancing corporate value and shareholder value over the medium to long term.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Continuation of the Performance-Linked Stock Compensation Plan | Astellas Pharma Inc. (4503) timely disclosure | Komori